BeiGene announced the opening of its flagship U.S. facility in Hopewell, New Jersey, at the Princeton West Innovation Campus, which houses biologics manufacturing capabilities and a clinical research and development center that further bolster the company’s differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flexibility to scale production of its innovative medicines in the future to meet the needs of patients with cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- BeiGene Announces New CFO Appointment and Senior Advisor Transition
- BeiGene names Aaron Rosenberg as CFO, succeeding Julia Wang
- BeiGene price target lowered to $152.50 from $180 at BofA
- BeiGene’s Xiaobin Wu sells over $233K in company shares
- BeiGene to present new data from SEQUOIA study of BRUKINSA